Menu

Image of the Day: Uncovered

Researchers discover cells in the early life stage of the Schistosoma mansoni parasite that contribute to adults’ reproductive systems.

Jul 12, 2018
Sukanya Charuchandra

ABOVE: This image from confocal microscopy shows a snail with its shell removed that is infected with schistosome parasites.
BO WANG, STANFORD UNIVERSITY 

Classified as the deadliest neglected tropical disease by the World Health Organization, schistosomiasis is caused by blood parasites of the genus Schistosoma that travel from snails to water to humans. In research published in eLife on July 10, scientists identify five cells from the parasites’ early stage of infection that form adult stem cells, a portion of which contribute to the growth of the reproductive system. 

Parasite eggs that hatch in water bodies take up residence in snails, within which they reproduce in large numbers. These organisms come into contact with humans through contaminated water. In the course of infection, the schistosomes pierce human skin and develop into adults upon reaching the liver. The sole treatment available for the infection kills adult worms in humans. 

“The drug used to fight schistosomes does not work on [the early] stage of infection,” Phillip Newmark, a professor of integrative biology at the University of Wisconsin-Madison and a coauthor of the study, says in a statement. “Understanding what’s happening in this early period after infection is critical, because it’s also a time when the parasites should be most vulnerable.”

B. Wang et al., “Stem cell heterogeneity drives the parasitic life cycle of Schistosoma mansoni,” eLife, doi:10.7554/eLife.35449, 2018.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.